-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

311.O1.6 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science

Symposia: Disorders of Platelet Number or Function: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Autoimmune disorders, Bleeding and Clotting, Bleeding disorders, Adult, AML, Acute Myeloid Malignancies, Combination therapy, Translational Research, Epidemiology, Platelet disorders, Clinical Research, Health outcomes research, Pediatric, Diseases, Thrombocytopenias, Immune Disorders, Therapy sequence, Real-world evidence, Treatment Considerations, Immunology, Young adult , Adverse Events, Biological Processes, Myeloid Malignancies, Molecular biology, Study Population, Human, Pathogenesis
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Room 30 (San Diego Convention Center)
Moderators:
Amanda B. Grimes, MD, Texas Children's Hospital and Deirdra R Terrell, PhD, University of Oklahoma Health Sciences Ctr
Disclosures:
Grimes: Novartis: Research Funding. Terrell: Sanofi: Other: advisory board.
12:00 PM

Saifur R. Chowdhury, PhD (c)1,2*, Emily Sirotich, PhD3,4, Dimpy Modi5*, Melanie St John5*, Kerolos Eisa5*, Adam Cuker, MD6, Carolyn E Beck7*, Rachael F Grace, MD8, Shuoyan Ning9*, Justin W Yan10*, Amanda Pfeiffer11*, Michele P Lambert, MD12,13*, Karen Panckeri14*, Allyson M Pishko, MD15, Kristine VanAarsen16*, Ahmed Slim17*, Kathryn M. Carrier18*, Rebecca Geer19*, Abinaya Arulselvan20*, Matthew Basara20*, Brenna Cannon20*, Ellis Bloom, DO21*, Sam J King20*, Daya Gill5*, Laura M. Venier5*, Emily Xu5*, Ishaq Siddiqui22*, Bonnie Liu5*, Taylah Buissereth, BS23*, Timothy Mercier24*, Emily M. Harris24*, Enass H. Raffa25,26*, Joel Livingston27*, Dongyoung Kim5*, Maryam Akbari-Moghaddam5,28*, Gordon Guyatt, MD29,30*, Dena Zeraatkar31,32*, Lehana Thabane31* and Donald Arnold, MD2,33

1Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada
2Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
3Michael G. DeGroote Centre for Transfusion Research, Department of Medicine, Hamilton, ON, Canada
4Yale School of Medicine, New Haven
5Michael G. DeGroote Centre for Transfusion Research, Department of Medicine, McMaster University, Hamilton, ON, Canada
6Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
7Hospital for Sick Children, Toronto, Canada
8Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA
9McMaster University, Hamilton, ON, CAN
10London Health Sciences Centre, Western University, London, Canada
11Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
12Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
13Division of Hematology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
14Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia
15Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
16London Health Sciences Centre, London, ON, Canada
17St. Joseph's Healthcare London, London, ON, Canada
18Harvard Medical School, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA
19Department of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
20The Children's Hospital of Philadelphia, Division of Hematology, Philadelphia
21Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA
22Faculty of Health Sciences, McMaster University, Hamilton, Canada
23Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
24Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston
25Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia
26Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
27Pediatric Hematology/KidClot, Department of Paediatrics, Stollery Children’s Hospital and University of Alberta, Edmonton, Canada
28Department of Computing and Software, McMaster University, Hamilton, ON, Canada
29Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, CAN
30Department of Medicine, McMaster University, Hamilton, Canada
31Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Canada
32Department of Anesthesia, McMaster University, Hamilton, Canada
33Department of Medicine, McMaster University, Hamilton, ON, Canada

12:15 PM

Alexandra Schifferli, MD1*, Nathalie Aladjidi, MD2,3*, Guillaume Moulis4,5*, Marlies Gisin6*, Guy Leverger, MD, PhD7*, Sebastien Heritier, MD8*, Thierry Leblanc9*, Helder Fernandes10*, Mony Fahd, MD MSc11* and Thomas Kuehne, MD12

1Oncology/Hematology, University Children's Hospital Basel, 4031 Basel, Switzerland
2Centre de Référence National des Cytopénies Autoimmunes de l’Enfant (CEREVANCE), Bordeaux University Hospital, Bordeaux, France
3Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Pediatric Hemato-Immunology, Bordeaux, AL, FRA
4Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
5Clinical Investigation Center 1436, Team PEPSS Pharmacologie en Population, cohorteS, biobanqueS, Toulouse University Hospital, Toulouse, France
6Departement of Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland
7Pediatric Hematology Oncology Immunology Department, Hôpital Trousseau, Paris, France
8Pediatric Hematology Oncology Immunology Department, Armand-Trousseau University Hospital, Paris, FRA
9Hopital Universitaire Robert-Debré, Paris, France
10Centre de Référence National des Cytopénies Autoimmunes de l’Enfant (CEREVANCE),, Bordeaux University Hospital, Bordeaux, France
11Pediatric hematology and immunology department, Robert-Debré Hospital, GHU APHP Nord Université Paris-Cité, Paris, France
12Department of Hematology/Oncology, University Children's Hospital UKBB, Basel, CHE

12:30 PM

Yoann Zadro, MD1,2*, Margaux Lafaurie1,3*, Maryse Lapeyre-Mestre1,3* and Guillaume Moulis1,2*

1Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse, France
2Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
3Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France

12:45 PM

Michelle MH Tan, MSc1*, Amna Malik, PhD2*, Jiawen Wang, BSc2*, Clara Lo, MD3*, Alice Hart4*, Nehal Joshi4*, Stuart Adams5*, Patrick Zhang, PhD6*, Katayoun Rezvani, MD, PhD6, Bing Zhang, MD7* and Nichola Cooper, MD2,4*

1Imperial College London, Centre for Haematology, Department of Immunology and Inflammation, London, ENG, United Kingdom
2Imperial College London, Centre for Haematology, Department of Immunology and Inflammation, London, United Kingdom
3Stanford University, Palo Alto, CA
4Imperial College Healthcare NHS Trust, London, United Kingdom
5Great Ormond Street Hospital for Children, London, United Kingdom
6Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Stanford Hospital & Clinics, Palo Alto, CA

1:00 PM

Mariia Kumskova, MD1, Gagan D. Flora, PhD1, Manasa K. Nayak, PhD1, Ivan Budnik, MD, PhD1*, Madankumar Ghatge, PhD1*, Neelam Chauhan, PhD1*, Aditi Jain1*, Janice Staber, MD2, Steven R. Lentz, MD, PhD1 and Anil K. Chauhan, PhD1

1University of Iowa, Iowa City, IA
2Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, IA

1:15 PM

Johan Rebetz, PhD1*, Genevieve Marcoux, PhD1*, Marc Bigaud, PhD2*, Elissa Furutani, MD3*, Tatjana Uffelmann, MSc2*, Sabina Pfister, PhD2*, Barbara Nüsslein-Hildesheim, PhD2*, Pascal Edrich, PhD2*, Isabelle Isnardi, PhD2*, Christoph Burkhart, PhD2* and John W Semple, PhD1,4

1Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
2Novartis Pharma AG, Basel, Switzerland
3Novartis Biomedical Research, Cambridge, MA
4Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden

*signifies non-member of ASH